ACADIA Pharmaceuticals Inc (MEX:ACAD)
MXN 509 0 (0%) Market Cap: 50.07 Bil Enterprise Value: 41.15 Bil PE Ratio: 83.33 PB Ratio: 4.82 GF Score: 75/100

ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2022 / 03:30PM GMT
Release Date Price: MXN466.2
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

Great. Good morning from the 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst, and it's my pleasure to introduce ACADIA Pharmaceuticals and CEO, Steve Davis.

(Operator Instructions)

So with that, Steve, thanks for joining us today, and let me turn things over to you for an update.

Stephen R. Davis
ACADIA Pharmaceuticals Inc. - CEO & Director

Great. Thank you, Cory. Hello, everyone, and thank you for joining us today. I'm Steve Davis, CEO of ACADIA Pharmaceuticals. I need to just note that the business of pharmaceutical development and commercialization has certain inherent risks, so please refer to our most recent SEC filings for a description of the risks related to our business.

I'd like to start this morning with a brief reminder of why we do what we do. What you see in this picture are faces of actual patients, their caregivers and family members and are the reason we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot